Miriam Leandro Dorta

Abstract Unresectable stage III NSCLC standard treatment is chemo-radiotherapy (CT-RT) followed by immunotherapy (IO) with durvalumab. We investigated adding an induction phase with chemo-immunotherapy (ChIO). APOLO was a multicentre, single-arm, phase 2 trial (NCT04776447). Non-resectable stage IIIA–IIIC NSCLC patients received induction ChIO (atezolizumab + carboplatin + paclitaxel, for 3 cycles), followed by concurrent CT-RT (3 cycles), and IO maintenance (atezolizumab for 16 cycles).

Font Type: Arial Georgia Verdana Line Spacing:    Column Width:    Open AccessArticle by Letícia Carrijo Masson 1, Carolina do Prado Servian 1, Vitor Hugo Jardim 1, Déborah dos Anjos 1, Miriam Leandro Dorta 1, João Victor Batalha-Carvalho 2, Ana Maria Moro 2,3, Pedro Roosevelt Torres Romão 4, Menira Souza 1, Fabiola Souza Fiaccadori 1 and Simone Gonçalves Fonseca 1,3,* 1 Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de...